MarketCap
Sarepta Therapeutics SRPT
$ 22.99
0.04%
Facebook
X
Telegram
Sarepta Therapeutics Total Assets | SRPT
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Sarepta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 1980 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.35 B | 3.96 B | 3.26 B | 3.13 B | 3.15 B | 2.98 B | 1.82 B | 1.64 B | 1.31 B | 424 M | 274 M | 295 M | 292 M | 205 M | 54.4 M | 46 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.96 B | 46 M | 1.64 B |
Quarterly Total Assets Sarepta Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.19 B | 3.18 B | 3.49 B | 3.68 B | 3.47 B | 3.96 B | 3.6 B | 3.42 B | 3.22 B | 3.26 B | 3.11 B | 3.13 B | 3.06 B | 3.13 B | 3.16 B | - | 3.06 B | 3.15 B | 2.66 B | 2.76 B | 2.77 B | 2.98 B | 2.98 B | 2.98 B | 2.98 B | 1.82 B | 1.82 B | 1.82 B | 1.82 B | 1.64 B | 1.64 B | 1.64 B | 1.64 B | 1.31 B | 1.31 B | 1.31 B | 1.31 B | 424 M | 424 M | 424 M | 424 M | 274 M | 274 M | 274 M | 274 M | 295 M | 295 M | 295 M | 295 M | 292 M | 292 M | 292 M | 292 M | 205 M | 205 M | 205 M | 205 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.96 B | 54.4 M | 1.69 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
12.3 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
11.2 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Codexis
CDXS
|
148 M | $ 1.42 | 0.33 % | $ 124 M | USA |
 |
Synthetic Biologics
SYN
|
38.2 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
986 M | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
2.61 B | - | - | $ 866 M |  China |
 |
Corner Growth Acquisition Corp.
COOL
|
1.97 M | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Qilian International Holding Group Limited
QLI
|
434 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
36.9 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Cue Biopharma
CUE
|
42.2 M | $ 27.67 | 2.63 % | $ 2.62 B | USA |
 |
CureVac N.V.
CVAC
|
803 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
1.06 B | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
1.4 B | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
7.2 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
3.07 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
489 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | Germany |
 |
Editas Medicine
EDIT
|
187 M | $ 3.08 | 0.33 % | $ 273 M | USA |
 |
Ardelyx
ARDX
|
502 M | $ 3.71 | 1.06 % | $ 894 M | USA |
 |
Affimed N.V.
AFMD
|
97.2 M | - | -34.95 % | $ 21.5 M | Germany |
 |
EyePoint Pharmaceuticals
EYPT
|
364 M | $ 4.57 | 0.21 % | $ 335 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 23.66 | 0.04 % | $ 3.01 B | USA |
 |
Assembly Biosciences
ASMB
|
258 M | $ 36.13 | 4.38 % | $ 405 M | USA |
 |
Fate Therapeutics
FATE
|
319 M | $ 2.42 | 0.61 % | $ 287 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
40.5 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
19.7 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
6.67 M | $ 6.66 | 5.38 % | $ 4.45 M | USA |
 |
Fortress Biotech
FBIO
|
186 M | $ 2.71 | 0.04 % | $ 75.6 M | USA |
 |
Generation Bio Co.
GBIO
|
231 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Anika Therapeutics
ANIK
|
190 M | $ 21.0 | 2.08 % | $ 301 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
8.18 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
1.66 B | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
690 M | $ 208.35 | 0.16 % | $ 10.4 B | USA |
 |
GlycoMimetics
GLYC
|
240 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
364 M | $ 57.46 | 2.9 % | $ 1.65 B | USA |
 |
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
261 M | - | 1083.1 % | $ 745 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
7.59 B | $ 66.43 | 0.04 % | $ 12.7 B | USA |
 |
BeiGene, Ltd.
BGNE
|
8.19 B | - | 0.49 % | $ 251 B |  Cayman-islands |